Carlsmed is a technology company.
Carlsmed has raised $104.0M across 3 funding rounds.
Carlsmed has raised $104.0M in total across 3 funding rounds.
Carlsmed has raised $104.0M in total across 3 funding rounds.
Carlsmed's investors include B Capital Group, Nextech Invest, SR One, U.S. Venture Partners, Heather Preston.
Carlsmed is a medical technology company developing the aprevo platform, an AI-driven, end-to-end system for personalized spine fusion surgery. It uses patient imaging data, predictive analytics, and 3D printing to create custom surgical plans and titanium implants tailored to individual anatomies, targeting complex adult spinal deformities in lumbar and cervical procedures.[1][2][3][5] The platform serves spine surgeons and patients suffering from spinal issues, solving the limitations of off-the-shelf implants by enabling precise alignment, reducing complications, and lowering revision rates while cutting healthcare costs.[1][3][4] Growth momentum is strong: Carlsmed went public in July 2025, raising $100.5 million; completed its first 50+ cervical cases; and launched the cervical aprevo system commercially in the U.S. on December 3, 2025, with an estimated $13.4 billion U.S. market for lumbar fusions alone.[2][3][4]
Carlsmed emerged from the 2019 acquisition of Precisive Surgical by Carlsmed, building on expertise in spine deformity correction devices.[1] Key leadership includes CEO Mike Cordonnier, who guides the company's focus on AI and data-driven personalization.[1] The idea stemmed from the challenge of vast imaging data available to surgeons but lacking effective analysis for surgical planning—Carlsmed's PACC (Predictive Alignment and Correction Characterization) platform bridges this by turning data into patient-specific cages, rods, and plans.[1][5] Early traction came from lumbar applications, with pivotal expansion to cervical surgeries marked by the first personalized cervical procedure on July 14, 2025, FDA Breakthrough Device designation, and rapid clinical adoption leading to the U.S. launch.[2][3][4]
Carlsmed rides the wave of AI in medtech and personalized medicine, transforming spine surgery—a field with ~445,000 annual U.S. lumbar procedures—by addressing misalignment risks from generic implants.[2][3] Timing aligns with surging demand for precision tech amid rising spine disorder cases, 3D printing maturity, and FDA support (e.g., Breakthrough Designation).[2][4] Favorable market forces include cost pressures on healthcare (aprevo reduces revisions/costs) and data explosion from imaging, enabling AI feedback loops.[1][3] It influences the ecosystem by complementing robots/navigation systems, gathering outcome data to advance industry standards, and expanding to international/cervical markets.[2][4]
Carlsmed is poised for acceleration post-IPO and cervical launch, with proceeds fueling R&D, clinical trials, regulatory wins, and global expansion—targeting 2026 cervical commercialization and beyond.[2][3] Trends like AI refinement from post-op data, broader spine applications, and value-based care will propel growth, potentially capturing significant share in a multi-billion market.[2][4] Its influence may evolve by setting benchmarks for personalized orthopedics, empowering surgeons with predictive tools to deliver superior, cost-effective outcomes—one patient-specific plan at a time.[1][3]
Carlsmed has raised $104.0M across 3 funding rounds. Most recently, it raised $64.0M Series C in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $64.0M Series C | B Capital Group, Nextech Invest, SR One, U.S. Venture Partners, Heather Preston | |
| Apr 1, 2022 | $30.0M Series B | B Capital Group, SR One, Heather Preston | |
| Dec 1, 2020 | $10.0M Series A | Nextech Invest, U.S. Venture Partners |